CN101389334A - 埃坡霉素d的给药方法 - Google Patents
埃坡霉素d的给药方法 Download PDFInfo
- Publication number
- CN101389334A CN101389334A CNA03815062XA CN03815062A CN101389334A CN 101389334 A CN101389334 A CN 101389334A CN A03815062X A CNA03815062X A CN A03815062XA CN 03815062 A CN03815062 A CN 03815062A CN 101389334 A CN101389334 A CN 101389334A
- Authority
- CN
- China
- Prior art keywords
- epothilone
- experimenter
- venoclysis
- administration
- treatment cycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 48
- XOZIUKBZLSUILX-UKMAFROXSA-N epothilone d Chemical compound O1C(=O)C[C@@H](O)C(C)(C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)CCC\C(C)=C/C[C@@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-UKMAFROXSA-N 0.000 title claims 18
- 238000001802 infusion Methods 0.000 claims abstract description 41
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 13
- 238000001990 intravenous administration Methods 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 22
- 230000002085 persistent effect Effects 0.000 claims 1
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 abstract description 67
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 4
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 abstract 2
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 abstract 2
- 231100000588 tumorigenic Toxicity 0.000 abstract 1
- 230000000381 tumorigenic effect Effects 0.000 abstract 1
- 102000029749 Microtubule Human genes 0.000 description 16
- 108091022875 Microtubule Proteins 0.000 description 16
- 210000004688 microtubule Anatomy 0.000 description 16
- 229930013356 epothilone Natural products 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 229930012538 Paclitaxel Natural products 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 229960001592 paclitaxel Drugs 0.000 description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 6
- 150000003883 epothilone derivatives Chemical class 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 4
- 229960002014 ixabepilone Drugs 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 3
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 2
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000013475 authorization Methods 0.000 description 2
- 229960002756 azacitidine Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- -1 carbonyl azacitidine Chemical compound 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960000961 floxuridine Drugs 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- 229960005304 fludarabine phosphate Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000003835 ketolide antibiotic agent Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 229960002340 pentostatin Drugs 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960001055 uracil mustard Drugs 0.000 description 2
- PFJFPBDHCFMQPN-RGJAOAFDSA-N (1s,3s,7s,10r,11s,12s,16r)-3-[(e)-1-[2-(aminomethyl)-1,3-thiazol-4-yl]prop-1-en-2-yl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CN)=N1 PFJFPBDHCFMQPN-RGJAOAFDSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- ZGMLACURZVGTPK-UHFFFAOYSA-N 5-fluoranyl-1h-pyrimidine-2,4-dione Chemical compound OC1=NC=C(F)C(O)=N1.FC1=CNC(=O)NC1=O ZGMLACURZVGTPK-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229940119336 Microtubule stabilizer Drugs 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 150000003885 epothilone B derivatives Chemical class 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38216602P | 2002-05-20 | 2002-05-20 | |
| US60/382,166 | 2002-05-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101389334A true CN101389334A (zh) | 2009-03-18 |
Family
ID=33476529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA03815062XA Pending CN101389334A (zh) | 2002-05-20 | 2003-05-20 | 埃坡霉素d的给药方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20040072882A1 (ja) |
| EP (1) | EP1575556A2 (ja) |
| JP (1) | JP2006514681A (ja) |
| KR (1) | KR20050043796A (ja) |
| CN (1) | CN101389334A (ja) |
| AU (1) | AU2003296878A1 (ja) |
| WO (1) | WO2004103267A2 (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2273083C (en) * | 1996-12-03 | 2012-09-18 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US8618085B2 (en) * | 2000-04-28 | 2013-12-31 | Koasn Biosciences Incorporated | Therapeutic formulations of desoxyepothilones |
| ATE350383T1 (de) * | 2002-08-23 | 2007-01-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen |
| US7649006B2 (en) * | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| AU2004268377B2 (en) * | 2003-09-02 | 2008-06-26 | Novartis Ag | Cancer treatment with epothilones |
| US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| US20050215604A1 (en) * | 2004-03-26 | 2005-09-29 | Kosan Biosciences, Inc. | Combination therapies with epothilones and carboplatin |
| EP2634252B1 (en) | 2005-02-11 | 2018-12-19 | University of Southern California | Method of expressing proteins with disulfide bridges |
| WO2007130501A2 (en) * | 2006-05-01 | 2007-11-15 | University Of Southern California | Combination therapy for treatment of cancer |
| JP5718808B2 (ja) | 2008-04-25 | 2015-05-13 | エーエスエム インターナショナル エヌ．ヴェー．Ａｓｍ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｎ．Ｖ． | テルルおよびセレン薄膜のａｌｄのための前駆体の合成および使用 |
| WO2010056901A2 (en) | 2008-11-13 | 2010-05-20 | University Of Southern California | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
| KR101829380B1 (ko) | 2009-10-26 | 2018-02-19 | 에이에스엠 인터내셔널 엔.브이. | ５ａ족 원소 함유 박막의 원자 층 증착용 전구체의 합성 및 용도 |
| EP3566719A1 (en) | 2010-05-18 | 2019-11-13 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU735900B2 (en) * | 1996-03-12 | 2001-07-19 | Pg-Txl Company, L.P. | Water soluble paclitaxel prodrugs |
| CA2273083C (en) * | 1996-12-03 | 2012-09-18 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| CA2311929A1 (en) * | 1997-12-04 | 1999-06-10 | Bristol-Myers Squibb Company | A process for the reduction of oxiranyl epothilones to olefinic epothilones |
| US6194181B1 (en) * | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| US6302838B1 (en) * | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
| EP1135470A2 (en) * | 1998-11-20 | 2001-09-26 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| WO2000061142A1 (en) * | 1999-04-14 | 2000-10-19 | Dana-Farber Cancer Institute, Inc. | Method and composition for the treatment of cancer |
| JP2004500388A (ja) * | 2000-03-01 | 2004-01-08 | スローン−ケッタリング インスティトュート フォア キャンサー リサーチ | エポチロン、その中間体およびその類似体の合成 |
| MXPA02010565A (es) * | 2000-04-28 | 2004-05-17 | Kosan Biosciences Inc | Produccion de policetidos. |
| JP2004516011A (ja) * | 2000-07-25 | 2004-06-03 | コーサン バイオサイエンシーズ， インコーポレイテッド | エポチロンのための発酵プロセス |
-
2003
- 2003-05-20 US US10/442,820 patent/US20040072882A1/en not_active Abandoned
- 2003-05-20 AU AU2003296878A patent/AU2003296878A1/en not_active Abandoned
- 2003-05-20 JP JP2004572190A patent/JP2006514681A/ja active Pending
- 2003-05-20 KR KR1020047018759A patent/KR20050043796A/ko not_active Application Discontinuation
- 2003-05-20 EP EP03817031A patent/EP1575556A2/en not_active Withdrawn
- 2003-05-20 WO PCT/US2003/017921 patent/WO2004103267A2/en active Application Filing
- 2003-05-20 CN CNA03815062XA patent/CN101389334A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006514681A (ja) | 2006-05-11 |
| KR20050043796A (ko) | 2005-05-11 |
| AU2003296878A1 (en) | 2004-12-13 |
| US20040072882A1 (en) | 2004-04-15 |
| AU2003296878A8 (en) | 2009-01-08 |
| WO2004103267A3 (en) | 2008-11-27 |
| WO2004103267A2 (en) | 2004-12-02 |
| EP1575556A2 (en) | 2005-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mazzaferro et al. | Oral delivery of anticancer drugs I: general considerations | |
| Piette et al. | Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial | |
| CN101389334A (zh) | 埃坡霉素d的给药方法 | |
| Reid et al. | Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors | |
| Chang et al. | Weekly paclitaxel in advanced non-small cell lung cancer | |
| KR20130140071A (ko) | 항종양 알칼로이드를 이용한 병용요법 | |
| Pentikis et al. | Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers | |
| Mukai et al. | Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors | |
| Zheng et al. | Pirarubicin-based chemotherapy displayed better clinical outcomes and lower toxicity than did doxorubicin-based chemotherapy in the treatment of non-metastatic extremity osteosarcoma | |
| Nontprasert et al. | Assessment of the neurotoxicity of oral dihydroartemisinin in mice | |
| US20060160756A1 (en) | Treatment and prevention of multi-drug resistance | |
| CN107921139A (zh) | 使用flavagline和2‑脱氧葡萄糖的组合疗法 | |
| Al-Ghananeem et al. | Advances in brain targeting and drug delivery of anti-HIV therapeutic agents | |
| KR20120050512A (ko) | 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료 | |
| Pujol et al. | Weekly paclitaxel combined with monthly carboplatin in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study | |
| TW201249435A (en) | Antitumoral combination comprising cabazitaxel and cisplatin | |
| Pal et al. | EXTH-80. PBI-200: in vivo efficacy of a novel, highly CNS-penetrant next generation TRK inhibitor | |
| KR20230043905A (ko) | 5-메틸-1,2,4-옥사디아졸-3-일 화합물의 저용량 요법 및 제제 | |
| Van Putten et al. | Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study | |
| CN103505450B (zh) | 洛铂在制备治疗前列腺癌药物中的应用 | |
| JP2008169220A (ja) | 癌を処置または予防するためのβ−ラパコンの使用 | |
| Ilyas-Feldmann et al. | Tolerability of tariquidar–A third generation P-gp inhibitor as add-on medication to antiseizure medications in drug-resistant epilepsy | |
| Giaccone et al. | Preliminary results of two dose-finding studies of Paclitaxel (Taxol) and carboplatin in Non-small Cell Lung and Ovarian | |
| US20100209348A1 (en) | Methods for determining liposome bioequivalence | |
| Gregianin et al. | Clinical and pharmacokinetic study of fractionated doses of oral etoposide in pediatric patients with advanced malignancies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090318 |